Histrelin Shortage: What Providers and Prescribers Need to Know in 2026

For prescribers managing patients on histrelin, 2026 presents a nuanced picture: one indication's medication (Vantas for prostate cancer) is permanently off the market, while the other (Supprelin LA for central precocious puberty) remains available but presents significant access challenges. This guide provides a current overview for prescribers — pediatric endocrinologists, urologists, oncologists, and primary care providers — on the state of histrelin availability and what it means for patient management.

Clinical Background: Two Histrelin Products, Two Different Availability Stories

Histrelin acetate, a synthetic nonapeptide GnRH agonist, was sold under two brand names: Supprelin LA (50 mg implant for CPP) and Vantas (50 mg implant for advanced prostate cancer). Both contained identical active ingredient concentrations and were manufactured at the same Endo Pharmaceuticals facility — yet they were not classified as interchangeable products.

Endo discontinued Vantas in September 2021 citing batch failures. As of 2026, no equivalent histrelin implant is available for the prostate cancer indication, and no generic has been approved. Prescribers managing advanced prostate cancer patients who were on Vantas should have already transitioned to alternative ADT options — but some patients may still present asking about Vantas specifically.

Supprelin LA: Current Access Landscape for CPP Prescribers

Supprelin LA remains the only FDA-approved once-yearly GnRH agonist implant for central precocious puberty in the US. Key access realities in 2026:

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop Supprelin LA is available exclusively through specialty pharmacies. The implant is shipped to the physician's office. No retail or mail-order pharmacy carries it.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop Billed under HCPCS J9226, not as a pharmacy benefit. Practices must have appropriate billing infrastructure in place.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop Every major payer requires PA for Supprelin LA. Documentation requirements typically include: confirmed CPP diagnosis, pubertal LH/FSH levels (or GnRH stimulation test results), and prescriber specialty (pediatric endocrinologist, or consultation note).

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop List price approximately $49,000 per implant. Private payer reimbursement ~$45,291 (January 2026 data). Medicare 20% co-insurance = ~$7,498. Even insured patients may face significant out-of-pocket costs.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop There is no FDA-approved generic histrelin implant as of 2026.

Prior Authorization Documentation: What Payers Require

Most payers require the following for Supprelin LA PA approval. Having these ready at the time of submission significantly reduces turnaround time:

ICD-10 diagnosis code E22.8 (Central precocious puberty) with clinical documentation of onset

Pubertal baseline LH/FSH levels or GnRH stimulation test results showing pubertal response

Patient age (≤11 for females, ≤12 for males per most payer criteria)

Prescriber specialty or consultation note from a pediatric endocrinologist

For gender dysphoria/gender-affirming use: additional criteria including behavioral health evaluation per WPATH guidelines (varies by payer)

GnRH Agonist Alternatives: A Clinical Comparison for Prescribers

When Supprelin LA access is delayed or denied, the following alternatives have similar efficacy for HPG axis suppression. Selection should consider patient age, weight, injection tolerance, insurance formulary, and family preference:

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop 1-month (7.5/11.25/15 mg IM) or 3-month (11.25/30 mg IM). Most long-term safety data. Most commonly prescribed. Weight-based dosing available.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop 6-month IM injection. Approved 2017. Reduces clinic visits. Different manufacturer (Arbor Pharmaceuticals) — independent supply chain from Lupron.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop 6-month subcutaneous injection. Approved 2020. Less painful than IM; 45 mg fixed dose.

All of the above require separate prior authorizations. Efficacy for HPG axis suppression is reported as similar across agents in head-to-head analyses, though sample sizes and study designs vary.

38,224+ patients found their medications in stock

38K+

Find Histrelin In Stock Today →

Patient Assistance and Manufacturer Support Programs

For patients facing coverage denials or affordability barriers, Endo Pharmaceuticals offers a Patient Assistance Program for Supprelin LA. The Supprelin LA Support Center (866-316-7263) provides dedicated reimbursement support, including assistance with prior authorization submissions, appeals, and connecting eligible patients with manufacturer support. Many practices find that engaging the Support Center early — before the PA is submitted — streamlines the process significantly.

How medfinder Can Help Your Patients

When patients are struggling to locate a specialty pharmacy that has Supprelin LA in stock, medfinder for providers can call pharmacies on their behalf to identify which ones can fill the prescription. This removes the burden from patients and families who may not know where to start.